Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. - Hsu, Man-Chen; Chang, Ru-Wen; Wang, Mu-Chun; Chen, Chia-Hui; Chen, Wen-Hua; Lee, Tzong-Shyuan; Wang, Chih-Hsien (Journal of Food & Drug Analysis, 2025)